Transdermal Delivery Systems: What are the Requirements for Pressure Sensitive Adhesives?

Sponsored by: LTS Lohmann Therapy Systems

Focused on:

  • Transdermal
  • Adhesives
  • Drug Delivery

Date: 25 October


Time: 3PM London/10AM New York

Alternative drug delivery methods form an important part of the current global pharmaceutical market and its differing patient profiles and needs.

Transdermal drug delivery is a form of drug administration in which the drug is administered through patient’s skin, and is driven by the introduction of easy-to-use and effective Transdermal Drug Delivery Systems (TDS) based on cutting-edge technology. To date, there are numerous transdermal products that have gained significant commercial success especially in therapeutic areas such as pain management, Alzheimer’s and Parkinson’s disease, sexual hormone replacement/contraception, smoking cessation, etc..

TDS are intended to deliver drugs across skin into the systemic circulation. Pressure-sensitive adhesive (PSA) is one of the most critical component used in a TDS – and an understanding of how PSAs work and operate will facilitate successful TDS product development.

This webinar will discuss the physico-chemical properties of pressure sensitive adhesives, and their importance for providing TDS with reversible adhesion to the skin. Furthermore it will show that PSAs also affects other critical quality attributes of the TDS such as drug delivery, flux through skin and physical and chemical stability of the finished product.

The webinar presentation will focus on poly acrylates and poly siloxanes as examples, as they are the most common polymers used in pressure sensitive adhesives.

Please join this webinar to learn more.

Presented by

Dr. Thomas Hille,


Dr.Thomas Hille is a pharmacist and obtained his postgraduate degrees from University of Bonn. He joined LTS in 1986. Currently he is heading a R&D lab developing TDS and oral thin films. Prior to LTS, he was with Knoll AG, Germany, heading a R & D lab developing solid dosage forms. Dr. Hille is co-inventor in more than 70 patents.

In the last two years he gave presentations in Marburg University, and Concept Heidelberg dealing with the quality by design (QbD) concept in the development of TDS and he was speaker in the A.F.E.R.A. congress and A.W.A conference presenting the pharmaceutical requirements in pressure sensitive adhesives and release liners, when used in TDS.

Key Learning Objectives

  • Learn about the physico-chemical properties of pressure sensitive adhesives based on poly acrylates and poly siloxanes
  • Learn how to formulate transdermal delivery systems to get a reversible adhesion to the skin and a successful drug delivery from the TDS into the skin


  • Formulation Scientist
  • Drug Delivery Scientists
  • R&D Scientist
  • Formulation Pharmacist
  • Heads of Research and Development
  • Head of Pharmaceutical Technology
  • Director of Formulation
  • Director Formulation Development
  • Head of Product Development
  • Heads of Innovation Technology